These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26856695)

  • 1. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
    Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
    Farokhnia M; Azarkolah A; Adinehfar F; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Sadeghi SM; Moghadam M; Gharibi F; Mirshafiee O; Akhondzadeh S
    Clin Neuropharmacol; 2013; 36(6):185-92. PubMed ID: 24201233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
    Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
    Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study.
    Rezaei F; Mesgarpour B; Jeddian A; Zeionoddini A; Mohammadinejad P; Salardini E; Shahriari M; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28421639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
    J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
    Nikbakhat MR; Arabzadeh S; Zeinoddini A; Khalili Z; Rezaei F; Mohammadinejad P; Ghaleiha A; Akhondzadeh S
    Pharmacopsychiatry; 2016 Jul; 49(4):162-9. PubMed ID: 26902281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
    Khodaie-Ardakani MR; Khosravi M; Zarinfard R; Nejati S; Mohsenian A; Tabrizi M; Akhondzadeh S
    Acta Med Iran; 2015; 53(6):337-45. PubMed ID: 26069170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.
    Honer WG; Thornton AE; Chen EY; Chan RC; Wong JO; Bergmann A; Falkai P; Pomarol-Clotet E; McKenna PJ; Stip E; Williams R; MacEwan GW; Wasan K; Procyshyn R;
    N Engl J Med; 2006 Feb; 354(5):472-82. PubMed ID: 16452559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
    Akhondzadeh S; Ghayyoumi R; Rezaei F; Salehi B; Modabbernia AH; Maroufi A; Esfandiari GR; Naderi M; Ghebleh F; Tabrizi M; Rezazadeh SA
    Psychopharmacology (Berl); 2011 Feb; 213(4):809-15. PubMed ID: 20949350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.